Increased relative risks noted for current or recent use of oral, injected, implanted, IUD progestogen-only contraceptives<\/p>\n<\/h3>\n
By Elana Gotkine HealthDay Reporter<\/b><\/p>\n
<\/b><\/p>\n
WEDNESDAY, March 22, 2023 (HealthDay News) — Progestogen-only contraceptive use is associated with a slight increase in breast cancer risk, according to a study published online March 21 in PLOS Medicine<\/em>.<\/p>\n Danielle Fitzpatrick, M.B.B.S., M.P.H., from the University of Oxford in the United Kingdom, and colleagues compared hormonal contraceptive prescriptions recorded prospectively in a U.K. primary care database in a nested case-control study involving 9,498 women aged younger than 50 years with incident invasive breast cancer (diagnosed in 1996 to 2017) and 18,171 controls.<\/p>\n The researchers found that 44 and 39 percent of women with breast cancer and matched controls, respectively, had a hormonal contraceptive prescription an average of 3.1 years before breast cancer diagnosis. Of the prescriptions, approximately half were for progestogen-only preparation. The odds ratios for breast cancer were increased significantly if the last hormonal contraceptive prescription was for oral combined, oral progestogen-only, injected progestogen, or progestogen-releasing intrauterine devices (IUDs; odds ratios, 1.23, 1.26, 1.25, and 1.32, respectively). Significantly increased relative risks were seen for current or recent use of progestogen-only contraceptives: 1.29, 1.18, 1.28, and 1.21 for oral, injected, implanted, and IUDs, respectively. On combination of these results with those from previously published studies, the 15-year absolute excess risk associated with five years of oral combined or progestogen-only contraceptives in high-income countries was estimated at eight and 265 per 100,000 users from age 16 to 20 and 35 to 39 years, respectively.<\/p>\n “Current or recent use of all types of progestogen-only contraceptives is associated with a slight increase in breast cancer risk, similar to that associated with use of combined oral contraceptives,” a coauthor said in a statement.<\/p>\n Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n <\/i><\/p>\n